Myriad Genetics Selects Lundbeck As European Partner for Flurizan

redorbit.com     May 22, 2008            

Posted on: Thursday, 22 May 2008, 06:00 CDT Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) today announced the selection of H. Lundbeck A/S for European commercialization of Flurizan(R), Myriad's lead therapeutic candidate for the treatment of Alzheimer's disease. Myriad and Lundbeck have... [read full story]                    


*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies